AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy

AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA

World's First: In Vivo Gene Editing Product ART002 Achieves Saturation of Pharmacological Effect in Humans and Reduces LDL-C Safely and Effectively

AccurEdit Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Phase One Trial of ART001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Polyneuropathy

AccurEdit's ART001 becomes the first product to demonstrate safe and effective systemic CRISPR gene editing in humans in China

ART001 is well tolerated by all patients treated and demonstrates an outstanding safety profile. No >Grade 1 liver enzyme elevation was observed in any of the patients treated. So far, no patient in the study experienced infusion-related reaction, which was observed in 38% of the patients treated with a similar product previously.

AccurEdit and N1 Life Form a Joint Venture Named ‘Napoltec’

AccurEdit Therapeutics (Suzhou) Co., Ltd. ("AccurEdit"), an emerging company based on new generations of safe...